Clinical Trial Update: Anti-HER2 Bispecific Antibody Zanidatamab (ZW25) Activity in Combination With Chemotherapy With/Without Tislelizumab [Phase 1, Phase 2]

View source ↗

Summary

Zanidatamab (ZW25) in combination with chemotherapy, with or without tislelizumab, is being evaluated in Phase 1/2 trials for breast cancer, gastric cancer, and…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Gastric Cancer
• Gastroesophageal Junction Cancer

Drugs mentioned

• Tislelizumab (tislelizumab)
• Zanidatamab (ZW25) (zanidatamab)

Snippet

Sponsor: BeiGene | Conditions: Breast Cancer, Gastric Cancer | Phase 1, Phase 2 | Status: COMPLETED